Overview
| Name | AlphaMissense · aliases: AlphaMissense |
|---|---|
| Full name | The paper gives no expanded name |
| Ambiguous names (not auto-linked) | AlphaFold |
| Family | Not a family entry. Record covers the missense model only; the sibling genomics and protein-design models have their own records |
| Organization | Google DeepMind |
| Organization type | Big-tech lab |
| Country | United Kingdom |
| Model class | Variant pathogenicity prediction (structure-augmented protein LM) |
| Domain | Genomics & RNA (also: Proteins) |
| First release | · journal Basis: Journal paper and developer blog on the same day source |
| Other milestones | |
| Latest update | · no later event Basis: Last repository commit: predictions-database licence update The latest sourced event for this model is the 2024-03 predictions-database licence update, after which the repository was archived. Note (not an update to this model): a 2026-09-08 variant-impact score is a downstream product of a different line and is sourced only second-hand Note: The site recorded 2026-09-08 as an update to this model; corrected source The most recent sourced event, not a claim that nothing changed since. |
| Status | Maintained only · No substantive event for the model itself since 2024-03; repository archived |
| Openness | Code: Open Weights: Closed Licence change: · docs update Basis: Predictions-database licence update (last repository commit) source The prediction catalogue is open including commercial use and the code is open; no weights release or licence text was retrieved this round |
| Benchmarks reported | 2 counted (modified protocol 1, retrospective 1) |
| Wet-lab validation | None recorded |
| Unverified fields | † background.products_partnerships, release_milestones.code_release, open_status.weights, open_status.code_license |
| As of | 2026-11-16 |
What it does
Starts from a co-folding protein structure model and fine-tunes on weak labels from variants that are common or absent in human and primate populations, scoring every possible single amino-acid substitution and publishing most of them as a precomputed catalogue for clinical and research lookup. Like popEVE it predicts missense effects, but it emphasises a proteome-wide catalogue while the other emphasises cross-gene calibration and rare-disease cohorts; sibling lines are AlphaGenome for genomics and AlphaProteo for protein design.
Benchmarks reported
Every row is one pairing from the survey's relation file; a score belongs to the benchmark page's ranking, where it is shown with metric, eval set, source type and date. 2 of 2 pairings are counted.
| Benchmark | Relation | Eval set / protocol | Source type | Note and evidence |
|---|---|---|---|---|
| 11 ClinVar hold-out protocol | Developer report, modified protocol | — | Self-reported | Its own missense test set · evidence |
| 13 CAGI | Retrospective dataset use | — | Third-party | Post-hoc third-party evaluation on CAGI6 (checked at abstract level) †partly verified · evidence |
Other evaluations (outside the 44)
- Deep mutational scanning correlation (Public benchmark not among the 44) Self-reported: The developer project page reports correlation on DMS data for about two dozen proteins, outside the 44
- Third-party variant-model comparison (preprint, abstract level) (Comparison against baselines only) Third-party: Another variant model's preprint uses it as a baseline and concedes partial tuning on a clinical variant database; abstract level only
Developers report: combining a structure model with population-frequency weak labels yields directly queryable pathogenicity predictions for proteome-wide missense substitutions and outperforms earlier evolutionary predictors.
Independent evidence: A third-party post-hoc evaluation exists (see the CAGI entry): it is listed as the best single non-meta predictor but behind meta predictors, and it was not a participant.
Training data
Group in Figure 7: Public data only.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Yes | Evolutionary information from protein sequence and structure plus allele frequencies from public population resources source |
| b. Private or licensed data | No | source |
| c. Own wet-lab data used for training | No | |
| d. Wet lab used only for validation | No | No own wet lab; model selection used a clinical variant database and the developers' own figure note concedes such methods may be overestimated on that benchmark source |
Wet-lab validation
None. The developers report no wet-lab validation.
Background
- Organization: The developer is the AI research unit of a listed US technology group (headquartered in London), funded internally with no separate financing; the prediction catalogue is free to use including commercially.
- Funding: Not disclosed
- Products and partnerships: The model derives from the group's co-folding structure series; a variant-impact score released on 2026-09-08 by a separate genomics product line is reported to combine this model's outputs, but only in second-hand sources and is not treated as an event for this model.
- Related models: AlphaFold 3, AlphaGenome, AlphaProteo, popEVE
Reading notes
- The self-reported clinical-variant figures come from a developer-built held-out set; same-named protocols in different papers are not directly comparable.
- High discrimination is not clinical usability; evidence strength depends on the likelihood ratio at the chosen threshold.
- Nearly every later variant model cites it as a baseline, yet it does not appear in the official ProteinGym summary tables, so "cited as a baseline" must not be read as "on the board".
- The leakage concern stems from model selection on a clinical variant database, not from training on it directly.
Caveats
- The CAGI entry is a post-hoc evaluation, not participation, and the source gives no overall rank.
- The held-out clinical variant set is developer-built, not an official split.
- No substantive event for the model itself since 2024-03; the repository is archived.
- The 2026 downstream score belongs to another product line and is sourced only second-hand.
Sources
- Journal paper 2023 (journal)
- Developer project page (official site)
- Code and predictions repository (repository)
- Third-party post-hoc evaluation paper (third-party paper)
- Downstream product line coverage (second-hand) (second-hand) second-hand
Corrections
3 corrections
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| benchmarks_reported[bench-13-cagi] | Ranked first among 60 predictors in CAGI6 | Post-hoc evaluation, not a participant; the paper calls it the best single (non-meta) predictor, tied with another non-meta predictor and behind two meta-predictors, with no overall ranking given | source | 2026-11-16 |
| latest_update | 2026-09-08, product update | 2024-03-13, no later sourced event found (the 2026 event belongs to another product line and is second-hand only) | source | 2026-11-16 |
| benchmarks_reported | Candidate pairing ProteinGym | Not a pairing: no entry for this model in either the official clinical or the DMS zero-shot summary tables | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.